Evidence map›Paper›PMID 32803109›Full record

ArticleJBMR plus2020

Gene Expression Profile and Acute Gene Expression Response to Sclerostin Inhibition in Osteogenesis Imperfecta Bone.

Rachel K Surowiec, Lauren F Battle, Stephen H Schlecht, Edward M Wojtys, Michelle S Caird, Kenneth M Kozloff

Open access · goldAbstract read
In one paragraph

Article in JBMR plus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Rachel K SurowiecDepartment of Biomedical Engineering University of Michigan Ann Arbor MI USA.ORCID https://orcid.org/0000-0001-7614-4412
Lauren F BattleDepartment of Orthopaedic Surgery University of Michigan Ann Arbor MI USA.
Stephen H SchlechtDepartment of Orthopaedic Surgery University of Michigan Ann Arbor MI USA.ORCID https://orcid.org/0000-0002-6857-927X
Edward M WojtysDepartment of Orthopaedic Surgery University of Michigan Ann Arbor MI USA.
Michelle S CairdDepartment of Orthopaedic Surgery University of Michigan Ann Arbor MI USA.
Kenneth M KozloffDepartment of Biomedical Engineering University of Michigan Ann Arbor MI USA.ORCID https://orcid.org/0000-0002-1108-7258
University of Michigan · US

Funding

Michigan Institute for Clinical and Health Research (MCHR)UL1TR000433 · NCATS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MASHOUR, GEORGE ALEXANDER · 2012 to 2016
$49.9M
Transforming Translational Science and Education to Benefit Human HealthUL1TR000043 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY · 2012 to 2015
$26.8M
Structure, Composition, & Histology Core - Core BP30AR069620 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KARL J JEPSEN · 2016 to 2026
$8.4M
Natural Variation in the Growth and Development of the ACL ComplexR00AR070903 · NIAMS · INDIANA UNIVERSITY INDIANAPOLIS · PI SCHLECHT, STEPHEN · 2019 to 2021
$739k
Natural Variation in the Growth and Development of the ACL ComplexK99AR070903 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHLECHT, STEPHEN · 2017 to 2018
$184k
NCATS NIH HHS UL1 TR000043NCATS NIH HHS UL1 TR000433NIAMS NIH HHS K99 AR070903NIAMS NIH HHS P30 AR069620NIAMS NIH HHS R00 AR070903
6 · The paper itself

Abstract

Sclerostin antibody (SclAb) therapy has been suggested as a novel therapeutic approach toward addressing the fragility phenotypic of osteogenesis imperfecta (OI). Observations of cellular and transcriptional responses to SclAb in OI have been limited to mouse models of the disorder, leaving a paucity of data on the human OI osteoblastic cellular response to the treatment. Here, we explore factors associated with response to SclAb therapy in vitro and in a novel xenograft model using OI bone tissue derived from pediatric patients. Bone isolates (approximately 2 mm

Indexed as

ANABOLIC THERAPYBONE FORMATIONOSTEOGENESIS IMPERFECTASCLEROSTIN ANTIBODYWNT SIGNALING

Identifiers

PMID32803109
PMCPMC7422710
OpenAlexW3029496867

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.